Every 10-Q that Benitec Biopharm (BNTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BNTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNTC filings page.
Benitec Biopharma Inc. reports results for the quarter and nine months ended March 31, 2026, as it advances its BB-301 genetic medicine for Oculopharyngeal Muscular Dystrophy (OPMD). The company generated no revenue and recorded a nine‑month net loss of $32.7 million.
Operating expenses reached $36.8 million for the nine months, driven by $15.5 million in research and development and $21.3 million in general and administrative costs, including higher share‑based compensation. Other income of $4.0 million, mainly from interest on cash, partially offset these losses.
Benitec strengthened its balance sheet, ending March 31, 2026 with $184.8 million in cash, cash equivalents and restricted cash, up from $97.9 million at June 30, 2025, after raising about $104.5 million in gross proceeds from common stock offerings and warrant exercises. Management states this cash should fund operations for at least twelve months while BB-301 progresses through its Phase 1b/2a program.
Benitec Biopharma Inc. reported another quarter as a clinical-stage biotech with no product revenue and continued investment in its genetic medicine platform. For the six months ended December 31, 2025, the company recorded a net loss of $20.8 million, compared with $14.6 million a year earlier, driven by higher research and development spending of $9.2 million and general and administrative expenses of $14.0 million.
Benitec significantly strengthened its balance sheet, ending the period with $188.8 million in cash and cash equivalents, up from $97.7 million at June 30, 2025, primarily from equity offerings that generated gross proceeds of about $104.5 million. Total assets were $190.7 million and stockholders’ equity was $187.4 million. Management states this cash should fund operations for at least the next twelve months as the company advances its lead OPMD gene therapy candidate BB-301 through an ongoing Phase 1b/2a program. Shares outstanding were 34,254,907 at December 31, 2025 and 34,354,334 as of February 6, 2026.
Benitec Biopharma (BNTC) reported quarterly results with no revenue and a net loss of $8.97 million for the three months ended September 30, 2025. Operating expenses were $9.80 million, led by R&D $3.37 million and G&A $6.43 million. Cash used in operating activities was $3.35 million.
The company ended the quarter with $94.5 million in cash and cash equivalents and stated this is sufficient to fund operations for at least the next twelve months from the date of the report. Subsequent to quarter-end, Benitec completed an underwritten offering of 5,930,000 shares at $13.50 and a concurrent registered direct sale of 1,481,481 shares at $13.50, for gross proceeds of approximately $100 million. Shares outstanding were 26,250,469 as of September 30, 2025; 33,862,226 were outstanding as of November 14, 2025. Benitec continues advancing BB-301, its silence-and-replace AAV gene therapy for OPMD, with multiple subjects treated in an ongoing Phase 1b/2a study.